Claudia R. Ball

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Integration and validation of complementary ex vivo assays for functional precision oncology.

Integration and validation of complementary ex vivo assays for functional precision oncology.

Journal: NPJ precision oncology

Published: October 30, 2025

Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.

Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.

Journal: Cell death discovery

Published: July 30, 2025

Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment.

Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment.

Journal: Biomolecules

Published: March 28, 2025

A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML.

A quiescence-like/TGF-β1-specific CRISPRi screen reveals drug uptake transporters as secondary targets of kinase inhibitors in AML.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: November 05, 2024

ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia.

ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia.

Journal: Cell reports

Published: November 05, 2024

Let's get functional: Drug sensitivity profiling to enable precision sarcoma medicine.

Let's get functional: Drug sensitivity profiling to enable precision sarcoma medicine.

Journal: Cell stem cell

Published: September 05, 2024

RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation.

RevCAR-mediated T-cell response against PD-L1-expressing cells turns suppression into activation.

Journal: NPJ precision oncology

Published: August 21, 2024

The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers.

The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers.

Journal: Cell death and differentiation

Published: June 07, 2024

Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.

Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.

Journal: Molecular cancer

Published: November 17, 2023

BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.

BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.

Journal: Science advances

Published: September 01, 2023

Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions.

Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions.

Journal: Nature communications

Published: March 23, 2023

Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity.

Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity.

Journal: Cell reports. Medicine

Published: December 19, 2022

Showing 1-12 of 49

Last Updated: 09/26/2026